Related Experiment Video

Updated: Oct 7, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Beyond remodeling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction

S D Solomon1

  • 1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, 02115, USA.

Journal of Cardiovascular Pharmacology
|June 8, 2001
PubMed

Insights

Angiotensin converting enzyme (ACE) inhibitors benefit heart failure patients and reduce mortality post-myocardial infarction. These drugs also show anti-ischemic effects, protecting against heart attacks.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Angiotensin converting enzyme (ACE) inhibitors were initially developed for hypertension.
  • They have demonstrated hemodynamic and survival benefits in congestive heart failure patients.
  • ACE inhibitors also attenuate ventricular remodeling and reduce mortality in patients with left ventricular dysfunction (LVD) post-myocardial infarction (MI).

Purpose of the Study:

  • To investigate the anti-ischemic potential of ACE inhibitors.
  • To explore the direct anti-atherosclerotic and anti-ischemic effects of ACE inhibitors.
  • To summarize recent clinical findings on ACE inhibitors' protection against ischemic events.

Main Methods:

  • Review of experimental literature on ACE inhibitors' effects.
  • Analysis of clinical trial data regarding ACE inhibitors and ischemic events.

Main Results:

  • ACE inhibitors confer hemodynamic and survival benefits in heart failure.
  • They attenuate ventricular remodeling and reduce mortality post-MI.
  • Clinical trials show significant protection from ischemic events with ACE inhibitors.

Conclusions:

  • ACE inhibitors possess direct anti-atherosclerotic and anti-ischemic properties.
  • They offer significant protection against myocardial infarction and other ischemic events.
  • The anti-ischemic potential of ACE inhibitors is supported by extensive research.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...